Skip to main content
letter
. 2011 Dec;32(11):E214. doi: 10.3174/ajnr.A2919

Fig 1.

Fig 1.

Kaplan-Meier curves for the cumulative probability of the primary end point after randomization in the PTAS and the medically treated groups in the SAMMPRIS trial and the probability in a hypothetical PTAS-treated cohort that provides the 35% relative risk reduction with PTAS treatment compared with medical treatment.